| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Meng-Na Zhang, Li-Ping Zou, Yang-Yang Wang, Ling-Yu Pang, Shu-Fang Ma, Lu-Lu Huang, Yang Gao, Qian Lu, David Neal Fran. Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis. Seizure. vol 60. 2018-10-15. PMID:29929111. |
tuberous sclerosis (tsc) is an autosomal dominant inherited disease caused by mutations in the tsc1 or tsc2 gene and results in the over-activation of the mammalian target of the rapamycin (mtor) signaling pathway. |
2018-10-15 |
2023-08-13 |
Not clear |
| David L Kolin, Kai Duan, Bo Ngan, J Ted Gerstle, Monika K Krzyzanowska, Gino R Somers, Ozgur Met. Expanding the Spectrum of Colonic Manifestations in Tuberous Sclerosis: L-Cell Neuroendocrine Tumor Arising in the Background of Rectal PEComa. Endocrine pathology. vol 29. issue 1. 2018-08-27. PMID:28733877. |
neuroendocrine tumorigenesis in tuberous sclerosis is often linked to inactivating mutations of tsc2 leading to aberrant activation of mammalian target of rapamycin (mtor) pathway. |
2018-08-27 |
2023-08-13 |
Not clear |
| Laura C Armstrong, Grant Westlake, John P Snow, Bryan Cawthon, Eric Armour, Aaron B Bowman, Kevin C Es. Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming. Human molecular genetics. vol 26. issue 23. 2018-05-24. PMID:28973543. |
tuberous sclerosis complex (tsc) is a pediatric disorder of dysregulated growth and differentiation caused by loss of function mutations in either the tsc1 or tsc2 genes, which regulate mtor kinase activity. |
2018-05-24 |
2023-08-13 |
human |
| Jonathan O Lipton, Lara M Boyle, Elizabeth D Yuan, Kevin J Hochstrasser, Fortunate F Chifamba, Ashwin Nathan, Peter T Tsai, Fred Davis, Mustafa Sahi. Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy. Cell reports. vol 20. issue 4. 2018-05-07. PMID:28746872. |
tuberous sclerosis complex (tsc) is a neurodevelopmental disorder characterized by mutations in either the tsc1 or tsc2 genes, whose products form a critical inhibitor of the mechanistic target of rapamycin (mtor). |
2018-05-07 |
2023-08-13 |
mouse |
| Miriam Schneider, Petrus J de Vries, Kai Schönig, Veit Rößner, Robert Walterei. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus. European archives of psychiatry and clinical neuroscience. vol 267. issue 5. 2018-01-30. PMID:27263037. |
mtor inhibitor reverses autistic-like social deficit behaviours in adult rats with both tsc2 haploinsufficiency and developmental status epilepticus. |
2018-01-30 |
2023-08-13 |
rat |
| Bing Han, Lulu Yu, Yuan Geng, Li Shen, Hualong Wang, Yanyong Wang, Jinhua Wang, Mingwei Wan. Chronic Stress Aggravates Cognitive Impairment and Suppresses Insulin Associated Signaling Pathway in APP/PS1 Mice. Journal of Alzheimer's disease : JAD. vol 53. issue 4. 2018-01-29. PMID:27392857. |
the phosphorylation of insulin receptor, insulin receptor substrate 1 and associated signaling pathways (akt, mtor, p70s6k, erk1/2, and pten) were decreased in hippocampus in app/ps1 mice compared to control mice, while no changes were found in gsk3 and tsc2 phosphorylation. |
2018-01-29 |
2023-08-13 |
mouse |
| Mark R Woodford, Rebecca A Sager, Elijah Marris, Diana M Dunn, Adam R Blanden, Ryan L Murphy, Nicholas Rensing, Oleg Shapiro, Barry Panaretou, Chrisostomos Prodromou, Stewart N Loh, David H Gutmann, Dimitra Bourboulia, Gennady Bratslavsky, Michael Wong, Mehdi Mollapou. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. The EMBO journal. vol 36. issue 24. 2017-12-28. PMID:29127155. |
the tumor suppressors tsc1 and tsc2 form the tuberous sclerosis complex (tsc), a regulator of mtor activity. |
2017-12-28 |
2023-08-13 |
Not clear |
| Juxiang Cao, Magdalena E Tyburczy, Joel Moss, Thomas N Darling, Hans R Widlund, David J Kwiatkowsk. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. The Journal of clinical investigation. vol 127. issue 1. 2017-09-06. PMID:27918305. |
tuberous sclerosis complex (tsc) is an autosomal dominant tumor-suppressor gene syndrome caused by inactivating mutations in either tsc1 or tsc2, and the tsc protein complex is an essential regulator of mtor complex 1 (mtorc1). |
2017-09-06 |
2023-08-13 |
human |
| Jian Yang, Paulina A Samsel, Kalin Narov, Ashley Jones, Daniel Gallacher, John Gallacher, Julian R Sampson, Ming Hong She. Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2 Neoplasia (New York, N.Y.). vol 19. issue 2. 2017-05-04. PMID:28092822. |
combination of everolimus with sorafenib for solid renal tumors in tsc2 tuberous sclerosis (tsc) is an inherited tumor syndrome caused by mutations in tsc1 or tsc2 that lead to aberrant activation of mtor and development of tumors in multiple organs including the kidneys. |
2017-05-04 |
2023-08-13 |
Not clear |
| Kristen D Starbuck, Richard D Drake, G Thomas Budd, Peter G Ros. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. Anticancer research. vol 36. issue 11. 2017-01-30. PMID:27793946. |
identification of mutations in the tuberous sclerosis 1 (tsc1) and tsc2 genes producing constitutive activation of the mammalian target of rapamycin (mtor) pathway presents an opportunity for targeted therapy. |
2017-01-30 |
2023-08-13 |
Not clear |
| Vinit V Patil, Miguel Guzman, Angela N Carter, Geetanjali Rathore, Daniel Yoshor, Daniel Curry, Angus Wilfong, Satish Agadi, John W Swann, Adekunle M Adesina, Meenakshi B Bhattacharjee, Anne E Anderso. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia. Neuropathology : official journal of the Japanese Society of Neuropathology. vol 36. issue 2. 2017-01-09. PMID:26381727. |
moreover, extracellular regulated kinase (erk) has been shown to phosphorylate s6 at serine 235/236 (s(235/236) ) and tuberous sclerosis complex 2 (tsc2) at serine 664 (s(664) ) leading to hyperactive mtor signaling. |
2017-01-09 |
2023-08-13 |
Not clear |
| Cyndi R Morales, Dan L Li, Zully Pedrozo, Herman I May, Nan Jiang, Viktoriia Kyrychenko, Geoffrey W Cho, Soo Young Kim, Zhao V Wang, David Rotter, Beverly A Rothermel, Jay W Schneider, Sergio Lavandero, Thomas G Gillette, Joseph A Hil. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Science signaling. vol 9. issue 422. 2016-12-20. PMID:27048565. |
we determined that the abundance of tuberous sclerosis complex 2 (tsc2), an mtor inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class i hdacs were inhibited. |
2016-12-20 |
2023-08-13 |
mouse |
| Cyndi R Morales, Dan L Li, Zully Pedrozo, Herman I May, Nan Jiang, Viktoriia Kyrychenko, Geoffrey W Cho, Soo Young Kim, Zhao V Wang, David Rotter, Beverly A Rothermel, Jay W Schneider, Sergio Lavandero, Thomas G Gillette, Joseph A Hil. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Science signaling. vol 9. issue 422. 2016-12-20. PMID:27048565. |
in neonatal rat cardiomyocytes, loss of tsc2 abolished hdac-dependent inhibition of mtor activity, and increased expression of tsc2 was sufficient to reduce hypertrophy in response to phenylephrine. |
2016-12-20 |
2023-08-13 |
mouse |
| Fu-Zheng Wei, Ziyang Cao, Xi Wang, Hui Wang, Mu-Yan Cai, Tingting Li, Naoko Hattori, Donglai Wang, Yipeng Du, Boyan Song, Lin-Lin Cao, Changchun Shen, Lina Wang, Haiying Wang, Yang Yang, Dan Xie, Fan Wang, Toshikazu Ushijima, Ying Zhao, Wei-Guo Zh. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy. vol 11. issue 12. 2016-10-31. PMID:26735435. |
downregulation of tsc2 (tuberous sclerosis 2) by ezh2 elicited mtor activation, which in turn modulated subsequent mtor pathway-related events, including inhibition of autophagy. |
2016-10-31 |
2023-08-13 |
human |
| Lyn M Moi. Lymphangioleiomyomatosis: Current understanding and potential treatments. Pharmacology & therapeutics. vol 158. 2016-10-26. PMID:26713679. |
these processes include mutational inactivation of the tuberous sclerosis complex genes, tsc1 and tsc2, activation of the mammalian target of rapamycin (mtor) pathway, enhanced cell proliferation and migration, lymphangiogenesis, metastatic spread through the blood and lymphatic circulations, sex steroid sensitivity and dysregulated autophagy. |
2016-10-26 |
2023-08-13 |
Not clear |
| Yu Gao, Ronald B Gartenhaus, Rena G Lapidus, Arif Hussain, Yanting Zhang, Xinghuan Wang, Han C Da. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells. Molecular cancer research : MCR. vol 13. issue 12. 2016-10-05. PMID:26374334. |
it has been reported that akt activates mtor through phosphorylation and inhibition of the tuberous sclerosis complex (tsc) protein tsc2. |
2016-10-05 |
2023-08-13 |
Not clear |
| Benjamin E Housden, Alexander J Valvezan, Colleen Kelley, Richelle Sopko, Yanhui Hu, Charles Roesel, Shuailiang Lin, Michael Buckner, Rong Tao, Bahar Yilmazel, Stephanie E Mohr, Brendan D Manning, Norbert Perrimo. Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi. Science signaling. vol 8. issue 393. 2016-06-06. PMID:26350902. |
the tuberous sclerosis complex (tsc) family of tumor suppressors, tsc1 and tsc2, function together in an evolutionarily conserved protein complex that is a point of convergence for major cell signaling pathways that regulate mtor complex 1 (mtorc1). |
2016-06-06 |
2023-08-13 |
human |
| Anna R Malik, Ewa Liszewska, Agnieszka Skalecka, Malgorzata Urbanska, Anand M Iyer, Lukasz J Swiech, Malgorzata Perycz, Kamil Parobczak, Patrycja Pietruszka, Malgorzata M Zarebska, Matylda Macias, Katarzyna Kotulska, Julita Borkowska, Wieslawa Grajkowska, Magdalena E Tyburczy, Sergiusz Jozwiak, David J Kwiatkowski, Eleonora Aronica, Jacek Jaworsk. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase. Acta neuropathologica communications. vol 3. 2016-04-21. PMID:26220190. |
tuberous sclerosis complex (tsc) is a genetic disease resulting from mutation in tsc1 or tsc2 and subsequent hyperactivation of mammalian target of rapamycin (mtor). |
2016-04-21 |
2023-08-13 |
Not clear |
| Angelika Mühlebner, Anand M Iyer, Jackelien van Scheppingen, Jasper J Anink, Floor E Jansen, Tim J Veersema, Kees P Braun, Wim G M Spliet, Wim van Hecke, Figen Söylemezoğlu, Martha Feucht, Pavel Krsek, Josef Zamecnik, Christian G Bien, Tilman Polster, Roland Coras, Ingmar Blümcke, Eleonora Aronic. Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression. Journal of neurodevelopmental disorders. vol 8. 2016-04-04. PMID:27042238. |
tuberous sclerosis complex (tsc) is a multisystem disorder that results from mutations in the tsc1 or tsc2 genes, leading to constitutive activation of the mammalian target of rapamycin (mtor) signaling pathway. |
2016-04-04 |
2023-08-13 |
Not clear |
| Hung Huynh, Huai-Xiang Hao, Stephen L Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N Balak, Michael R Palmer, Yan Wang, Benjamin H Lee, Dalila Sellami, Andrew X Zhu, Robert Schlegel, Alan Huan. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular cancer therapeutics. vol 14. issue 5. 2016-02-01. PMID:25724664. |
tuberous sclerosis complex (tsc), a heterodimer of tsc1 and tsc2, functions as a negative regulator of mtor signaling. |
2016-02-01 |
2023-08-13 |
Not clear |